Current and Emerging Systemic Therapies for Renal Cell Carcinoma: Clinical Evidence and Guideline Recommendations
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This educational program is intended for oncologists, urologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.
Upon completion of this activity, participants should be able to:
- Review clinical data on systemic treatment approaches for patients with operable, advanced or metastatic RCC
- Identify patients most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
- Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
- Apply guideline-directed therapeutic strategies to optimize the sequence of therapies in order to provide the best outcome to patients with RCC
- Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
- Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
Brian A. Costello, MD, MS
Associate Professor of Oncology and Urology
Division of Medical Oncology
Eric Jonasch, MD
Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Brian A. Costello, MD, MS
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Eric Jonasch, MD
Aravive: Consulting Fee
Arrowhead Pharmaceuticals, Inc.: Grant/Research Support
AVEO Pharmaceuticals, Inc.: Consulting Fee
Eisai Inc.: Consulting Fee
Exelixis Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
NiKang Therapeutics, Inc.: Consulting Fee; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Elizabeth R. Plimack, MD, MS
Astellas Pharma US, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
AstraZeneca/MedImmune: Consulting Fee; Scientific Advisor
AVEO Pharmaceuticals, Inc.: Consulting Fee; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support
Bristol-Myers Squibb/Medarex: Consulting Fee; Scientific Advisor
Calithera Biosciences, Inc.: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Genentech/Roche: Grant/Research Support
Infinity Pharmaceuticals, Inc: Consulting Fee; Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee; Scientific Advisor
MEI Pharma, Inc.: Consulting Fee; Scientific Advisor
Merck & Co., Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Pfizer Inc.: Consulting Fee; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Consulting Fee; Scientific Advisor
Seattle Genetics, Inc.: Consulting Fee; Scientific Advisor
NCCN and CCO Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-22-039-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until March 29, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing